This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Day One Biopharmaceuticals Framtida tillväxt
Future kriterier kontrolleras 5/6
Day One Biopharmaceuticals förväntas öka intäkter och intäkter med 64.9% respektive 24.8% per år. EPS förväntas tillväxt med 65% per år. Avkastningen på eget kapital förväntas bli -1.2% om 3 år.
Viktig information
64.9%
Tillväxttakt i vinsten
65.03%
Tillväxttakt för EPS
| Biotechs vinsttillväxt | 25.4% |
| Intäkternas tillväxttakt | 24.8% |
| Framtida avkastning på eget kapital | -1.21% |
| Bevakning av analytiker | Good |
| Senast uppdaterad | 24 Apr 2026 |
Senaste uppdateringarna om framtida tillväxt
Recent updates
Uppdatering av berättelse • Apr 13
DAWN: Servier Cash Offer Will Define Deal Outcome And Future Pipeline Path
Analysts have reset their Day One Biopharmaceuticals price targets to $21.50, generally aligning with Servier's agreed $21.50 per share cash acquisition price. They are also shifting ratings to more neutral stances, as upside potential is now seen as capped by the deal terms.Uppdatering av berättelse • Mar 29
DAWN: Servier Cash Offer Will Frame Deal Completion And Pipeline Optionality
Analysts have reset their price targets on Day One Biopharmaceuticals to $21.50, a move of up to $3.00 from prior estimates. They are aligning their models with the agreed $21.50 per share cash acquisition by Servier and see limited scope for additional upside from standalone growth assumptions.Uppdatering av berättelse • Mar 15
DAWN: Servier Cash Offer Will Define Future Upside And Downside Potential
The analyst price target for Day One Biopharmaceuticals has shifted from $22.25 to $21.50, with analysts aligning their views to the agreed $21.50 per share cash acquisition price from Servier and adjusting their assumptions around revenue growth, profit margins, discount rate, and future P/E accordingly. Analyst Commentary Following the Servier agreement, Street research has largely converged around the US$21.50 cash offer, with multiple firms cutting ratings to Neutral or Hold and aligning price targets with the acquisition price.
Uppdatering av berättelse • Mar 01
DAWN: Ojemda Franchise And Mersana Integration Will Recast Future Earnings Power
Analysts nudged their price target on Day One Biopharmaceuticals up by $1 to $30, reflecting updated assumptions around revenue growth, profitability, and future P/E, now that recent Street research has incorporated both the latest quarterly results and ongoing Ojemda development plans. Analyst Commentary Bullish analysts are framing the latest price target move to $30 as part of a broader, constructive view on Day One Biopharmaceuticals, grounded in updated revenue, profitability, and P/E assumptions around the Ojemda franchise and recent quarterly results.Seeking Alpha • Feb 27
Day One Biopharmaceuticals: Commercial Performance With Catalysts Ahead
Summary Day One Biopharmaceuticals, Inc.'s Q4 '25 came with net product revenues of $52.8M, up 36% from the prior quarter. DAWN's 2026 guidance for U.S. net product revenues of $225M-$250M implies 50% growth over 2025 at the midpoint of that guidance. Key catalysts include clinical readouts from Emi-Le and DAY-301 in 2026. A readout from FIREFLY-2 could come in mid-2027. Read the full article on Seeking Alpha
Uppdatering av berättelse • Feb 15
DAWN: Future Cash Flows From Mersana Acquisition Will Drive Upside Potential
Analysts raised their fair value estimate for Day One Biopharmaceuticals by $1 to $17.00, citing updated assumptions that combine higher revenue expectations, a higher future P/E, and a slightly higher discount rate. Analyst Commentary Recent Street research on Day One Biopharmaceuticals reflects a mix of optimism about the company’s potential and caution about execution risks and valuation.Uppdatering av berättelse • Feb 01
DAWN: Mersana Acquisition Will Recast Pipeline Risk Profile And Future Earnings Power
Narrative Update: Day One Biopharmaceuticals Analysts have adjusted their price target on Day One Biopharmaceuticals from US$27 to US$29, reflecting updated views on the Mersana acquisition, revised assumptions for future revenue growth and profit margins, and a higher future P/E multiple, even as some recent research has featured lower individual price targets. Analyst Commentary Recent Street research around Day One Biopharmaceuticals has centered on the acquisition of Mersana Therapeutics and how that deal reshapes the company’s pipeline, risk profile, and potential long term earnings power.Analysartikel • Jan 21
Optimistic Investors Push Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Up 31% But Growth Is Lacking
Despite an already strong run, Day One Biopharmaceuticals, Inc. ( NASDAQ:DAWN ) shares have been powering on, with a...Uppdatering av berättelse • Jan 08
DAWN: Mersana Acquisition And OJEMDA Durability Data Will Reshape Pipeline Risk Profile
Analysts have adjusted their price target on Day One Biopharmaceuticals from US$34.00 to US$27.00, citing updated assumptions on growth, margins and future P/E, along with support for the recently announced, higher cost acquisition of Mersana Therapeutics as a way to diversify the pipeline beyond OJEMDA. Analyst Commentary Bullish analysts are framing the Mersana deal as a sign that Day One is willing to pay up to secure assets that fit tightly with its focus on targeted oncology, even if the acquisition cost of up to US$285 million looks full on headline terms.Uppdatering av berättelse • Dec 23
DAWN: Mersana Deal Will Diversify ADC Platform And Support Future Upside
Analysts nudged their price target on Day One Biopharmaceuticals slightly higher to $22.25 per share, citing cautious optimism that the $285 million Mersana acquisition could diversify the pipeline beyond OJEMDA and enhance long term growth prospects despite its premium valuation. Analyst Commentary Bullish Takeaways Bullish analysts view the acquisition of Mersana as a strategic way to add a second antibody drug conjugate, Emi Le, alongside PTK7.Analysartikel • Dec 19
We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Easily Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Uppdatering av berättelse • Dec 09
DAWN: Mersana Acquisition Will Diversify ADC Pipeline And Support Long Term Upside
Analysts slightly raised their price target for Day One Biopharmaceuticals to $22.25 per share, citing the strategically bold, though expensive, acquisition of Mersana Therapeutics as a catalyst for pipeline diversification beyond OJEMDA and as a potential source of long term value. Analyst Commentary Analyst reactions to the Mersana deal highlight a mix of strategic enthusiasm and execution risk, with many viewing the transaction as a meaningful but high stakes swing for Day One's long term growth profile and valuation.Uppdatering av berättelse • Nov 25
DAWN: Acquisition of ADC Candidate Will Broaden Pipeline and Patient Reach
Analysts have lowered their price target for Day One Biopharmaceuticals from $24.25 to $22.25. They cited uncertainty over the recent $285 million Mersana acquisition, despite noting improved profit margin and revenue projections.Analysartikel • Nov 08
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Fly 29% But Investors Aren't Buying For Growth
Day One Biopharmaceuticals, Inc. ( NASDAQ:DAWN ) shares have continued their recent momentum with a 29% gain in the...Analysartikel • Nov 07
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
Day One Biopharmaceuticals, Inc. ( NASDAQ:DAWN ) just released its latest quarterly results and things are looking...Analysartikel • Sep 06
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Held Back By Insufficient Growth Even After Shares Climb 30%
Day One Biopharmaceuticals, Inc. ( NASDAQ:DAWN ) shareholders would be excited to see that the share price has had a...Uppdatering av berättelse • Aug 07
Expanded Clinical Indications And European Approvals Will Shape Future Oncology
Despite a substantially improved net profit margin and a lower future P/E ratio indicating enhanced profitability and valuation, the consensus analyst price target for Day One Biopharmaceuticals has been reduced from $26.25 to $24.00. Valuation Changes Summary of Valuation Changes for Day One Biopharmaceuticals The Consensus Analyst Price Target has fallen from $26.25 to $24.00.Analysartikel • Jul 18
We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Ny berättelse • Apr 29
FDA Approval And Ipsen Licensing Will Expand Pediatric Treatment Options
FDA approval and the launch of OJEMDA boost long-term revenue growth, addressing unmet medical needs and strong market uptake in pediatric glioma.Seeking Alpha • Feb 03
Day One Biopharmaceuticals: A Successful Launch In Pediatric Cancer
Summary Day One Biopharma's OJEMDA received FDA accelerated approval in 2024 for relapsed/refractory BRAF-altered pediatric low-grade glioma, with strong Phase 2 trial results and ongoing Phase 3 studies. Despite OJEMDA's 2024 sales reaching $57.2 million, market concerns persist due to its small patient population and competition from Novartis' BRAF-targeted therapy. Day One's pipeline includes DAY301, targeting PTK7 in solid tumors, but its early-stage development suggests FDA approval is years away. Given current market conditions and future catalysts, I rate Day One Biopharma as a Hold, with potential for a more bullish outlook based on revenue growth and pipeline progress. Read the full article on Seeking AlphaSeeking Alpha • Jan 07
Top 5 Commercial Biotech Buyout Candidates: Day One Biopharmaceuticals (No. 5)
Summary Day One Biopharmaceuticals focuses on pediatric cancer treatments, with a promising pipeline including tovorafenib and other targeted therapies. The stock has experienced a bearish trend but has significant upside potential, with Wall Street targeting a 190% increase. Strong financial position with $558.4M in cash and a cash runway of over 3 years significantly reducing the dilution risk. Potential peak sales of $800M-$1B and a valuation upside of 215%-294%, making DAWN a compelling investment opportunity. Read the full article on Seeking AlphaAnalysartikel • Nov 04
Forecast: Analysts Think Day One Biopharmaceuticals, Inc.'s (NASDAQ:DAWN) Business Prospects Have Improved Drastically
Celebrations may be in order for Day One Biopharmaceuticals, Inc. ( NASDAQ:DAWN ) shareholders, with the analysts...Analysartikel • Jul 12
We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Seeking Alpha • Jul 07
Day One Biopharmaceuticals: Still Uncertainty After FDA Approval
Summary Today, we circle back to Day One Biopharmaceuticals as the company's stock has dropped some even after its first FDA approval in late April. Analysts are optimistic about Day One Biopharmaceuticals, with numerous buy ratings and price targets ranging from $33 to $40 a share. The stock currently trades for less than $14/share. Despite the FDA approval, there is still some uncertainty as there are several moving parts to this story. An updated analysis follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Apr 24
Day One Pharmaceuticals: Ojemda Approval A Big Win, Current Valuation Fair
Summary Day One Biopharmaceuticals, Inc. secured accelerated approval for its lead drug tovorafenib yesterday in pediatric brain cancer. The drug will be marketed and sold as Ojemda. Ojemda will be able to address a larger patient population that Novartis' currently approved Mekinist - perhaps 2-3k patients per annum. That opens up a market opportunity of ~$1bn, and peak revenue opportunity of $500 - $600m, I estimate. As a loss-making company that must complete a post-marketing study of Ojemda before full approval is granted, current market cap valuation of ~$1.4bn seems fair. Read the full article on Seeking AlphaAnalysartikel • Mar 18
We're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Seeking Alpha • Feb 01
Navigating Day One Biopharmaceuticals' Financial Health And Clinical Prospects
Summary Day One Biopharmaceuticals is a leader in pediatric oncology, with a focus on addressing the unmet needs of pediatric cancer patients. The company has a strong financial position, with enough cash to fund operations through 2026, and is progressing through clinical trials with promising results. Day One's lead product candidate, tovorafenib, has the potential to redefine the standard of care for pediatric low-grade glioma, pending regulatory approval. Read the full article on Seeking AlphaAnalysartikel • Dec 04
We're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analysartikel • Jun 19
We're Not Very Worried About Day One Biopharmaceuticals' (NASDAQ:DAWN) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Prognoser för vinst- och omsättningstillväxt
| Datum | Intäkter | Intäkter | Fritt kassaflöde | Kassaflöde från rörelsen | Genomsnittligt Antal analytiker |
|---|---|---|---|---|---|
| 12/31/2028 | 407 | 30 | 118 | 58 | 5 |
| 12/31/2027 | 318 | -25 | 77 | 19 | 6 |
| 12/31/2026 | 242 | -91 | -45 | -113 | 6 |
| 12/31/2025 | 158 | -107 | -108 | -104 | N/A |
| 9/30/2025 | 134 | -152 | -125 | -120 | N/A |
| 6/30/2025 | 188 | -95 | -124 | -63 | N/A |
| 3/31/2025 | 162 | -69 | -165 | -87 | N/A |
| 12/31/2024 | 131 | -95 | -152 | -78 | N/A |
| 9/30/2024 | 102 | -84 | -162 | -89 | N/A |
| 6/30/2024 | 8 | -167 | -197 | -177 | N/A |
| 3/31/2024 | N/A | -209 | -174 | -171 | N/A |
| 12/31/2023 | N/A | -189 | -150 | -147 | N/A |
| 9/30/2023 | N/A | -175 | -144 | -141 | N/A |
| 6/30/2023 | N/A | -166 | -127 | -127 | N/A |
| 3/31/2023 | N/A | -157 | -114 | -114 | N/A |
| 12/31/2022 | N/A | -142 | -110 | -110 | N/A |
| 9/30/2022 | N/A | -124 | -88 | -88 | N/A |
| 6/30/2022 | N/A | -105 | -77 | -77 | N/A |
| 3/31/2022 | N/A | -183 | -60 | -60 | N/A |
| 12/31/2021 | N/A | -171 | -57 | -49 | N/A |
| 9/30/2021 | N/A | -183 | -49 | -41 | N/A |
| 6/30/2021 | N/A | -167 | -41 | -33 | N/A |
| 3/31/2021 | N/A | -54 | -29 | -21 | N/A |
| 12/31/2020 | N/A | -41 | -14 | -13 | N/A |
Analytiker Framtid Tillväxt Prognoser
Intäkter kontra sparande: DAWN förväntas bli lönsam under de kommande 3 åren, vilket anses vara snabbare än sparkvoten ( 3.4% ).
Resultat vs marknad: DAWN förväntas bli lönsam under de kommande 3 åren, vilket anses överstiga genomsnittet på marknaden.
Höga tillväxtresultat: DAWN förväntas bli lönsam under de kommande 3 åren.
Intäkt vs marknad: DAWN s intäkter ( 24.8% per år) förväntas växa snabbare än US marknaden ( 12.7% per år).
Hög tillväxtintäkter: DAWN s intäkter ( 24.8% per år) förutspås växa snabbare än 20% per år.
Tillväxtprognoser för vinst per aktie
Framtida avkastning på eget kapital
Framtida ROE: DAWN förväntas bli olönsam om 3 år.
Upptäck tillväxtföretag
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/04/25 20:53 |
| Aktiekurs vid dagens slut | 2026/04/22 00:00 |
| Intäkter | 2025/12/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa denna rapport finns på vår Github-sida; vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Day One Biopharmaceuticals, Inc. bevakas av 4 analytiker. 6 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Naureen Quibria | Capital One Securities, Inc. |
| Andrea Newkirk | Goldman Sachs |
| Ami Fadia | Needham & Company |